[{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"809a5a24-0dcc-468c-9efb-bbf00e2b961d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120283","created_at":"2023-11-07T16:14:26.813Z","updated_at":"2025-02-25T14:10:17.825Z","phase":"Phase 1","brief_title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","source_id_and_acronym":"NCT06120283","lead_sponsor":"BeiGene","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-17"},{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"89c18e67-5d9f-4f4c-836e-d176238b546e","acronym":"CAMBRIA-1","url":"https://clinicaltrials.gov/study/NCT05774951","created_at":"2023-03-20T20:03:21.727Z","updated_at":"2025-02-25T15:20:21.062Z","phase":"Phase 3","brief_title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","source_id_and_acronym":"NCT05774951 - CAMBRIA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 4300","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 04/20/2027","primary_completion_date":" 04/20/2027","study_txt":" Completion: 05/29/2036","study_completion_date":" 05/29/2036","last_update_posted":"2025-02-11"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2025-02-25T16:43:29.841Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-02-06"},{"id":"972ad6b2-046a-4952-a809-07b8eb832df8","acronym":"CALGB-40503","url":"https://clinicaltrials.gov/study/NCT00601900","created_at":"2021-01-18T02:13:51.918Z","updated_at":"2025-02-25T16:35:58.371Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","source_id_and_acronym":"NCT00601900 - CALGB-40503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 394","initiation":"Initiation: 09/24/2008","start_date":" 09/24/2008","primary_txt":" Primary completion: 06/30/2014","primary_completion_date":" 06/30/2014","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"d32e8658-c9d2-4f04-9c89-06bcade2de1e","acronym":"RxPONDER","url":"https://clinicaltrials.gov/study/NCT01272037","created_at":"2021-01-18T05:08:42.199Z","updated_at":"2025-02-25T16:36:08.722Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","source_id_and_acronym":"NCT01272037 - RxPONDER","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5018","initiation":"Initiation: 01/15/2011","start_date":" 01/15/2011","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-02-06"},{"id":"08f4f7cb-1de9-4017-ba99-77f7d20628d0","acronym":"ARTS-021-1001","url":"https://clinicaltrials.gov/study/NCT05867251","created_at":"2023-05-19T13:05:01.323Z","updated_at":"2025-02-25T16:46:48.865Z","phase":"Phase 1/2","brief_title":"Study of AVZO-021 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT05867251 - ARTS-021-1001","lead_sponsor":"Avenzo Therapeutics, Inc.","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-05"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"4de118f4-f565-48f1-9ed6-83996e6bbbe2","acronym":"DEBRA","url":"https://clinicaltrials.gov/study/NCT04852887","created_at":"2021-04-21T11:53:33.835Z","updated_at":"2025-02-25T16:53:39.381Z","phase":"Phase 3","brief_title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","source_id_and_acronym":"NCT04852887 - DEBRA","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1670","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2041","study_completion_date":" 07/01/2041","last_update_posted":"2025-02-04"},{"id":"971ccbcc-807b-4f19-a719-95e21b179631","acronym":"C4551001","url":"https://clinicaltrials.gov/study/NCT04606446","created_at":"2021-01-19T20:31:32.792Z","updated_at":"2025-02-25T16:53:21.614Z","phase":"Phase 1","brief_title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04606446 - C4551001","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • CDKN2A","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 03/07/2027","study_completion_date":" 03/07/2027","last_update_posted":"2025-02-04"},{"id":"fbf3716a-0c89-444d-8fe3-c713df6342b5","acronym":"RaPhLRR","url":"https://clinicaltrials.gov/study/NCT05467891","created_at":"2022-07-21T12:57:26.496Z","updated_at":"2025-02-25T15:54:32.807Z","phase":"Phase 2","brief_title":"Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05467891 - RaPhLRR","lead_sponsor":"Oana Danciu","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-31"},{"id":"b411be81-667e-4173-a340-a9d384984b56","acronym":"EUROPA","url":"https://clinicaltrials.gov/study/NCT04134598","created_at":"2021-01-18T20:11:54.546Z","updated_at":"2025-02-25T17:30:03.177Z","phase":"Phase 3","brief_title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","source_id_and_acronym":"NCT04134598 - EUROPA","lead_sponsor":"Azienda Ospedaliero-Universitaria Careggi","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 926","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 04/08/2025","primary_completion_date":" 04/08/2025","study_txt":" Completion: 04/08/2030","study_completion_date":" 04/08/2030","last_update_posted":"2025-01-30"},{"id":"1bc0890a-1931-45f9-86be-541afa2f8663","acronym":"","url":"https://clinicaltrials.gov/study/NCT02778685","created_at":"2021-01-18T13:37:54.643Z","updated_at":"2025-02-25T17:35:45.267Z","phase":"Phase 2","brief_title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT02778685","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib) • fulvestrant • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"be7d6188-2112-45b6-8dd9-1605ed39cec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294225","created_at":"2021-01-18T20:50:11.614Z","updated_at":"2025-02-25T17:36:33.824Z","phase":"Phase 2","brief_title":"Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT04294225","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 04/28/2020","start_date":" 04/28/2020","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2025-01-28"},{"id":"ec583cea-b73e-4568-91d2-545510d640f1","acronym":"LEPRE","url":"https://clinicaltrials.gov/study/NCT05601700","created_at":"2025-02-25T18:07:59.797Z","updated_at":"2025-02-25T18:07:59.797Z","phase":"Phase 3","brief_title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","source_id_and_acronym":"NCT05601700 - LEPRE","lead_sponsor":"Ente Ospedaliero Ospedali Galliera","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 09/22/2029","primary_completion_date":" 09/22/2029","study_txt":" Completion: 09/22/2029","study_completion_date":" 09/22/2029","last_update_posted":"2025-01-27"}]